Doksi-Hem

General characteristics. Structure:

Active agent: calcium of a dobezilat monohydrate of 521.51 mg that corresponds to the content of calcium of a dobezilat of 500 mg

Excipients: starch corn, magnesium stearate.

Structure of a cover of the capsule: titanium dioxide (E171), dye ferrous oxide yellow (E172), dye ferrous oxide black (E172), dye indigo carmine (indigotin I) (E132), gelatin.

Pharmacological properties:

The drug improving microcirculation. The vasoprotective, influences an endothelium of vessels. Normalizes a hyperpermeability of a vascular wall, increases capillary resistance, improves microcirculation, slows down aggregation of thrombocytes, reduces viscosity of blood, reduces activity of plasmatic kinin.

Pharmacokinetics. Absorption. Calcium добезилат it is slowly absorbed from a GIT. Cmax in blood after intake is observed in 5-6 h.

Distribution. Linkng with proteins of plasma makes 20-25%. Calcium добезилат practically does not get through GEB.

Removal. T1/2 of calcium of a dobezilat makes 24 h. It is removed, generally by kidneys during 24 h.

Indications to use:

— vascular defeats with the increased fragility and permeability of capillaries (including a diabetic retinopathy and a nephropathy);
— the mikroangiopatiya connected with various cardiovascular and exchange diseases;
— venous insufficiency of various degree of manifestation and its effect (including a prevaricose state with hypostasis of fabrics, pains, paresthesias, a congestive dermatosis; superficial phlebitis; varicosity; trophic ulcers).

Route of administration and doses:

The average recommended dose - 500 mg of 3 times/days during food within 2-3 weeks, then reduce a dose to 500 mg of 1 times/days.
At a retinopathy and a mikroangiopatiya - 500 mg of 3 times/days within 4-6 months, then 500 mg/days.

Features of use:

At the heavy renal failure demanding carrying out dialysis it is necessary to reduce a drug dose Doksi-hem.
It is possible to appoint drug for the purpose of prevention.
Use in pediatrics
Clinical data on efficiency and safety of use of drug Doksi-hem at children are absent.

Influence on ability to driving of motor transport and to control of mechanisms
The drug Doksi-hem does not influence ability to driving of motor transport and control of mechanisms.

Side effects:

Seldom: an allergic dermatosis, feverish reactions, a headache, dizzinesses, disturbances from a GIT.

Interaction with other medicines:

So far data on clinically significant interaction of drug Doksi-hem with other medicines are absent.

Contraindications:

— the bleedings caused by reception of anticoagulants;
— I trimester of pregnancy;
— hypersensitivity to calcium to a dobezilat.

Use of the drug DOKSI-XEM® at pregnancy and feeding by a breast
Drug is contraindicated to use in the I trimester of pregnancy. Data on safety and efficiency of use of drug Doksi-hem in the period of a lactation (breastfeeding) are not provided.

Use at renal failures
At the heavy renal failure demanding carrying out dialysis it is necessary to reduce a drug dose Doksi-hem.

Use for children
Clinical data on efficiency and safety of use of drug Doksi-hem at children are absent.

Overdose:

Data on drug overdose Doksi-hem are not provided.

Storage conditions:

Drug should be stored in protected from moisture, the place, unavailable to children, at a temperature from 15 °C to 25 °C.

Issue conditions:

According to the recipe

Packaging:

Капс. 500 mg: 30 pieces.